Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Aug;60(8):672–678. doi: 10.1136/thx.2004.030411

Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study

M M van der Eerden 1, F Vlaspolder 1, C S de Graaff 1, T Groot 1, W Bronsveld 1, H Jansen 1, W Boersma 1
PMCID: PMC1747487  PMID: 16061709

Abstract

Background: There is much controversy about the ideal approach to the management of community acquired pneumonia (CAP). Recommendations differ from a pathogen directed approach to an empirical strategy with broad spectrum antibiotics.

Methods: In a prospective randomised open study performed between 1998 and 2000, a pathogen directed treatment (PDT) approach was compared with an empirical broad spectrum antibiotic treatment (EAT) strategy according to the ATS guidelines of 1993 in 262 hospitalised patients with CAP. Clinical efficacy was primarily determined by the length of hospital stay (LOS). Secondary outcome parameters for clinical efficacy were assessment of therapeutic failure on antibiotics, 30 day mortality, duration of antibiotic treatment, resolution of fever, side effects, and quality of life.

Results: Three hundred and three patients were enrolled in the study; 41 were excluded, leaving 262 with results available for analysis. No significant differences were found between the two treatment groups in LOS, 30 day mortality, clinical failure, or resolution of fever. Side effects, although they did not have a significant influence on the outcome parameters, occurred more frequently in patients in the EAT group than in those in the PDT group (60% v 17%, 95% CI –0.5 to –0.3; p<0.001).

Conclusions: An EAT strategy with broad spectrum antibiotics for the management of hospitalised patients with CAP has comparable clinical efficacy to a PDT approach.

Full Text

The Full Text of this article is available as a PDF (125.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AUSTRIAN R., GOLD J. PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. Ann Intern Med. 1964 May;60:759–776. doi: 10.7326/0003-4819-60-5-759. [DOI] [PubMed] [Google Scholar]
  2. Bartlett J. G., Dowell S. F., Mandell L. A., File Jr T. M., Musher D. M., Fine M. J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000 Sep 7;31(2):347–382. doi: 10.1086/313954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boyter A. C., Stephen J., Fegan P. G., Nathwani D. Why do patients with infection remain in hospital once changed to oral antibiotics? J Antimicrob Chemother. 1997 Feb;39(2):286–288. doi: 10.1093/jac/39.2.286b. [DOI] [PubMed] [Google Scholar]
  4. Dunn A. S., Peterson K. L., Schechter C. B., Rabito P., Gotlin A. D., Smith L. G. The utility of an in-hospital observation period after discontinuing intravenous antibiotics. Am J Med. 1999 Jan;106(1):6–10. doi: 10.1016/s0002-9343(98)00359-3. [DOI] [PubMed] [Google Scholar]
  5. Eron L. J., Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med. 2001 Jan 8;161(1):61–65. doi: 10.1001/archinte.161.1.61. [DOI] [PubMed] [Google Scholar]
  6. Fang G. D., Fine M., Orloff J., Arisumi D., Yu V. L., Kapoor W., Grayston J. T., Wang S. P., Kohler R., Muder R. R. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990 Sep;69(5):307–316. doi: 10.1097/00005792-199009000-00004. [DOI] [PubMed] [Google Scholar]
  7. Farber B. F., Cooper D. J. Observing patients after antibiotics are discontinued. N Engl J Med. 1995 Oct 19;333(16):1083–1084. doi: 10.1056/NEJM199510193331616. [DOI] [PubMed] [Google Scholar]
  8. Farr B. M., Kaiser D. L., Harrison B. D., Connolly C. K. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax. 1989 Dec;44(12):1031–1035. doi: 10.1136/thx.44.12.1031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. File T. M., Jr, Segreti J., Dunbar L., Player R., Kohler R., Williams R. R., Kojak C., Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997 Sep;41(9):1965–1972. doi: 10.1128/aac.41.9.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fine M. J., Auble T. E., Yealy D. M., Hanusa B. H., Weissfeld L. A., Singer D. E., Coley C. M., Marrie T. J., Kapoor W. N. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243–250. doi: 10.1056/NEJM199701233360402. [DOI] [PubMed] [Google Scholar]
  11. Fine M. J., Medsger A. R., Stone R. A., Marrie T. J., Coley C. M., Singer D. E., Akkad H., Hough L. J., Lang W., Ricci E. M. The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 1997 Jan 13;157(1):47–56. [PubMed] [Google Scholar]
  12. Fine M. J., Smith M. A., Carson C. A., Mutha S. S., Sankey S. S., Weissfeld L. A., Kapoor W. N. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996 Jan 10;275(2):134–141. [PubMed] [Google Scholar]
  13. Gleason P. P., Meehan T. P., Fine J. M., Galusha D. H., Fine M. J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999 Nov 22;159(21):2562–2572. doi: 10.1001/archinte.159.21.2562. [DOI] [PubMed] [Google Scholar]
  14. Gordon Kelley A., Biedenbach Douglas J., Jones Ronald N. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2003 Aug;46(4):285–289. doi: 10.1016/s0732-8893(03)00087-7. [DOI] [PubMed] [Google Scholar]
  15. Gould I. M. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999 Apr;43(4):459–465. doi: 10.1093/jac/43.4.459. [DOI] [PubMed] [Google Scholar]
  16. Hook E. W., 3rd, Horton C. A., Schaberg D. R. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA. 1983 Feb 25;249(8):1055–1057. [PubMed] [Google Scholar]
  17. Kalin M., Ortqvist A., Almela M., Aufwerber E., Dwyer R., Henriques B., Jorup C., Julander I., Marrie T. J., Mufson M. A. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis. 2000 Aug 17;182(3):840–847. doi: 10.1086/315760. [DOI] [PubMed] [Google Scholar]
  18. Knaus W. A. Changing the cause of death. JAMA. 1983 Feb 25;249(8):1059–1060. [PubMed] [Google Scholar]
  19. Lieberman D., Schlaeffer F., Boldur I., Lieberman D., Horowitz S., Friedman M. G., Leiononen M., Horovitz O., Manor E., Porath A. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996 Feb;51(2):179–184. doi: 10.1136/thx.51.2.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lim W. S., Macfarlane J. T., Boswell T. C., Harrison T. G., Rose D., Leinonen M., Saikku P. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001 Apr;56(4):296–301. doi: 10.1136/thorax.56.4.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Menéndez R., Ferrando D., Vallés J. M., Martínez E., Perpiñ M. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur Respir J. 2001 Jul;18(1):151–156. doi: 10.1183/09031936.01.00090001. [DOI] [PubMed] [Google Scholar]
  22. Metlay J. P., Fine M. J., Schulz R., Marrie T. J., Coley C. M., Kapoor W. N., Singer D. E. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med. 1997 Jul;12(7):423–430. doi: 10.1046/j.1525-1497.1997.00074.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mundy L. M., Auwaerter P. G., Oldach D., Warner M. L., Burton A., Vance E., Gaydos C. A., Joseph J. M., Gopalan R., Moore R. D. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1309–1315. doi: 10.1164/ajrccm.152.4.7551387. [DOI] [PubMed] [Google Scholar]
  24. Mundy L. M., Oldach D., Auwaerter P. G., Gaydos C. A., Moore R. D., Bartlett J. G., Quinn T. C. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest. 1998 May;113(5):1201–1206. doi: 10.1378/chest.113.5.1201. [DOI] [PubMed] [Google Scholar]
  25. Niederman M. S., Bass J. B., Jr, Campbell G. D., Fein A. M., Grossman R. F., Mandell L. A., Marrie T. J., Sarosi G. A., Torres A., Yu V. L. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993 Nov;148(5):1418–1426. doi: 10.1164/ajrccm/148.5.1418. [DOI] [PubMed] [Google Scholar]
  26. Niederman M. S., Mandell L. A., Anzueto A., Bass J. B., Broughton W. A., Campbell G. D., Dean N., File T., Fine M. J., Gross P. A. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001 Jun;163(7):1730–1754. doi: 10.1164/ajrccm.163.7.at1010. [DOI] [PubMed] [Google Scholar]
  27. Ramirez J. A., Vargas S., Ritter G. W., Brier M. E., Wright A., Smith S., Newman D., Burke J., Mushtaq M., Huang A. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999 Nov 8;159(20):2449–2454. doi: 10.1001/archinte.159.20.2449. [DOI] [PubMed] [Google Scholar]
  28. Rosón B., Carratalà J., Dorca J., Casanova A., Manresa F., Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis. 2001 Jun 15;33(2):158–165. doi: 10.1086/321808. [DOI] [PubMed] [Google Scholar]
  29. Rosón B., Carratalà J., Verdaguer R., Dorca J., Manresa F., Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis. 2000 Oct 12;31(4):869–874. doi: 10.1086/318151. [DOI] [PubMed] [Google Scholar]
  30. San Pedro G. S., Campbell G. D., Jr Limitations of diagnostic testing in the initial management of patients with community-acquired pneumonia. Semin Respir Infect. 1997 Dec;12(4):300–307. [PubMed] [Google Scholar]
  31. Sanyal S., Smith P. R., Saha A. C., Gupta S., Berkowitz L., Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med. 1999 Jul;160(1):346–348. doi: 10.1164/ajrccm.160.1.9806048. [DOI] [PubMed] [Google Scholar]
  32. Stout J. E., Yu V. L. Legionellosis. N Engl J Med. 1997 Sep 4;337(10):682–687. doi: 10.1056/NEJM199709043371006. [DOI] [PubMed] [Google Scholar]
  33. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]
  34. Wise R., Hart T., Cars O., Streulens M., Helmuth R., Huovinen P., Sprenger M. Antimicrobial resistance. Is a major threat to public health. BMJ. 1998 Sep 5;317(7159):609–610. doi: 10.1136/bmj.317.7159.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. van Kasteren M. E., Wijnands W. J., Stobberingh E. E., Janknegt R., van der Meer J. W. Optimaliseren van het antibioticabeleid in Nederland. II. SWAB-richtlijnen voor antimicrobiële therapie bij thuis opgelopen pneumonie en bij nosocomiale pneumonie. Ned Tijdschr Geneeskd. 1998 Apr 25;142(17):952–956. [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Web-only appendices]
thorax_60_8_672__index.html (1.6KB, html)
thorax_60_8_672__1.pdf (21.6KB, pdf)
thorax_60_8_672__2.pdf (24KB, pdf)

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES